Nippon Shinyaku Patents – Insights & Stats

Nippon Shinyaku has a total of 1870 patents globally, out of which 780 have been granted. Of these 1870 patents, more than 56% patents are active. Japan is where Nippon Shinyaku has filed the maximum number of patents, followed by United States of America and Europe. Parallelly, Japan seems to be the main focused R&D centre and also is the origin country of Nippon Shinyaku.

Nippon Shinyaku was founded in the year 1911. The Company manufactures pharmaceutical and health foods products. The Company produces drugs for urinary, nerve, respiratory and circulatory systems as well as analgesic and anti-inflammatory drugs. Nippon Shinyaku also develops synthetic anti-bacterial agents. As of March 2023, the market cap of Nippon Shinyaku is $3.03 Billion.

Do read about some of the most popular patents of Nippon Shinyaku which have been covered by us in this article and also you can find Nippon Shinyaku patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Nippon Shinyaku patent portfolio.

How many patents does the founder of Nippon Shinyaku have?

The founder Hisomu Ichinose has 1 patent

How many patents does Nippon Shinyaku have?

Nippon Shinyaku has a total of 1870 patents globally. These patents belong to 422 unique patent families. Out of 1870 patents, 1057 patents are active.

How Many Patents did Nippon Shinyaku File Every Year?

Nippon Shinyaku Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantNippon Shinyaku Applications FiledNippon Shinyaku Patents Granted
202315
20227132
20216660
202017085
201912547
20188533
20175263
20168655
201511628
20142639
20134246
20125540

Which Nippon Shinyaku Drug Patents are Expiring in the Next 10 Years?

The patent no. US9079934B2 which is expiring in Aug, 2031, describing invention that offers an oligomer that effectively induces the skipping of the 53rd exon in the human dystrophin gene. Additionally, a pharmaceutical composition with high efficiency in causing this exon skipping is provided.

Given below is the list of few drugs patented by Nippon Shinyaku accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.

Drug NamePatent NumberPatent TitlePatent Expiration
ViltepsoUS9079934B2Antisense nucleic acidsAug, 2031

How many Nippon Shinyaku patents are Alive/Dead?

Nippon Shinyaku Patent Portfolio

 How Many Patents did Nippon Shinyaku File in Different Countries?

Nippon Shinyaku Worldwide Patent Filing

Countries in which Nippon Shinyaku Filed Patents

CountryPatents
Japan258
United States Of America145
Europe129
China97
Korea (South)93
Canada77
Australia73
India58
Germany56
Mexico51
Brazil49
Russia49
Taiwan44
Spain31
Hong Kong (S.A.R.)28
South Africa27
Indonesia27
Viet Nam27
Philippines26
Israel25
Denmark24
Portugal23
Austria21
Hungary19
Malaysia19
Singapore19
Norway19
Colombia19
Poland18
Slovenia17

Where are Research Centres of Nippon Shinyaku Patents Located?

R&D Centers of Nippon Shinyaku

 10 Best Nippon Shinyaku Patents

WO2002088084A1 is the most popular patent in the Nippon Shinyaku portfolio. It has received 170 citations so far from companies like Toray Industries, Cardio and Sandoz.

Below is the list of 10 most cited patents of Nippon Shinyaku:

Publication NumberCitation Count
WO2002088084A1170
WO2012029986A1165
WO2013100190A1137
WO2012043730A1128
WO2006022323A180
WO2004002963A180
WO2009157398A160
US7205302B259
WO2010090290A159
WO2003037862A158

How many inventions of other companies were rejected due to Nippon Shinyaku patents?

The statistics below share strategic R&D insights. It tells the companies that were trying to protect inventions similar to Nippon Shinyaku invention. They couldn’t because Nippon Shinyaku had protected those before them.

Examiners at the USPTO referred 22 Nippon Shinyaku patents in 79 rejections (35 USC § 102 or 35 USC § 103 types).

The top citing companies in the Nippon Shinyaku patent portfolio are Sarepta Therapeutics, Belrose Pharma and Biomarin Technologies.

List of the Companies whose Patents were rejected citing Nippon Shinyaku –

CompanyNumber of Patent Applications that faced Rejection Citing Nippon Shinyaku PatentsNumber of Rejections (102 & 103)
Sarepta Therapeutics816
Belrose Pharma25
Biomarin Technologies23
Biorelevantcom23
Academisch Ziekenhuis Leiden11
Snu R&Db Foundation11
Mizkan Holdings12
Bend Research12
Toray Industries12
Bio Ved Pharmaceuticals11

Count of 102 and 103 Type Rejections based on Nippon Shinyaku Patents

Top Nippon Shinyaku Patents used in Rejecting Most Patent Applications

Patent NumberCount of Rejected Applications
US9079934B29
US6537561B15
US9512424B23
US6468565B13
US20080020990A12
US7205302B22
US20130225548A12
US20090137790A11
US6994283B11
US20060166315A11
US7198803B21
US7144906B21
US20070190081A11
US8282956B21
US7728131B21

What are Nippon Shinyaku key innovation segments?

What Technologies are Covered by Nippon Shinyaku?

The chart below distributes patents filed by Nippon Shinyaku in different countries on the basis of the technology protected in patents. It also represents the markets where Nippon Shinyaku thinks it’s important to protect particular technology inventions.

R&D Focus: How has Nippon Shinyaku search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Nippon Shinyaku?

Related Articles

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.